New England Patriots sign DT Jeremiah Pharms Jr.

New England's one-year, $1.005M signing of Pharms Jr. earns a C Contract Value Index (CVI) — a neutral, risk-balanced deal that reflects modest depth reinforcement on a minimal financial commitment. At that salary band, this is a low-cost probe for a rotation-caliber defensive tackle with limited recent opportunity; the Patriots are essentially betting that developmental or injury-recovery potential justifies a training camp or practice-squad audition rather than a premium roster spot. The single-year structure eliminates long-term liability and keeps the deal well below any franchise commitment threshold, which is appropriate for a signing of this profile — it's the kind of no-stakes roster move that contending teams make routinely to add depth without constraint. However, the C-grade signals that the contract doesn't represent exceptional value, meaning either the performance tier doesn't justify the price point (unlikely at $1M) or the overall strategic fit remains unclear without fuller context on the team's defensive line health or scheme needs. For a Patriots roster currently positioned as an AFC East contender, this is organizational prudence: low risk, low reward, zero cap consequence.